# Sumatriptan

## Imigran FDT 50mg

| TAH Drug Code      | [OIMI5](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OIMI5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Migraine, moderate to severe, acute treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Dosing             | 50 to 100 mg as a single dose. If symptoms persist or return, may repeat dose (usually same as first dose) after >2 hours. Maximum dose: 100 mg/dose; 200 mg per 24 hours. [Lexi-Drug] [仿單]Maximum dose: 300 mg per 24 hours.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | Hypersensitivity (eg, angioedema, anaphylaxis) to sumatriptan or any component of the formulation; ischemic heart disease or signs or symptoms of ischemic heart disease (coronary artery vasospasm, Prinzmetal angina, angina pectoris, MI, silent myocardial ischemia); history of cerebrovascular syndromes (including strokes, transient ischemic attacks), history of hemiplegic or basilar migraine; peripheral vascular disease (including ischemic bowel disease); uncontrolled hypertension; use within 24 hours of ergotamine derivatives; use within 24 hours of another 5-HT1 agonist; concurrent administration or within 2 weeks of discontinuing an MAO type A inhibitors; Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders; severe hepatic impairment. Uncontrolled HTN. Concomitant use of ergotamine or its derivatives (including methysergide). |
| Adverse Effects    | 1% to 10%: Cardiovascular: Chest pain (<=2%), chest pressure (<=2%), chest tightness (<=2%), hot and cold flashes (3%) Gastrointestinal: Sore throat (<=3%) Local: Local pain (2%) Nervous system: Fatigue (<=3%), feeling of heaviness (<=3%), heaviness of chest (<=2%), malaise (<=3%), pain (<=8%), paresthesia (3% to 5%), sensation of pressure (<=8%), sensation of tightness (<=3%), vertigo (2%) Neuromuscular & skeletal: Jaw pain (<=3%), jaw pressure (<=3%), jaw tightness (<=3%), neck pain (<=3%) Respiratory: Pharyngeal edema (<=3%)                                                                                                                                                                                                                                                                                                                                                                                 |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sumatriptan-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

